[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Argenx Se ADR (ARGX)

Argenx Se ADR (ARGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Argenx Se ADR LAARDERHOOGTWEG 25 AMSTERDAM P7 1101EB NLD

www.argenx.com Employees: 1,863 P: 31-10-703-8441

Sector:

Medical

Description:

argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands.

Key Statistics

Overview:

Market Capitalization, $K 54,583,640
Enterprise Value, $K 51,092,348
Shares Outstanding, K 62,188
Float, K 60,677
% Float 97.57%
Short Interest, K 1,807
Short Float 2.91%
Days to Cover 6.89
Short Volume Ratio 0.69
% of Insider Shareholders 2.43%
% of Institutional Shareholders 60.32%

Financials:

Annual Sales, $ 4,248 M
Annual Net Income, $ 1,292 M
Last Quarter Sales, $ 1,313 M
Last Quarter Net Income, $ 366,000 K
EBIT, $ 1,309 M
EBITDA, $ 1,337 M

Growth:

1-Year Return 63.17%
3-Year Return 121.43%
5-Year Return 179.80%
5-Year Revenue Growth 6,719.79%
5-Year Earnings Growth 247.14%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 5.52 on 05/07/26
Next Earnings Date 07/30/26
Earnings Per Share ttm 22.46
EPS Growth vs. Prev Qtr -31.17%
EPS Growth vs. Prev Year 113.95%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

ARGX Ratios

Ratio
Price/Earnings ttm 39.73
Price/Earnings forward 34.07
Price/Earnings to Growth 1.36
Return-on-Equity % 44.37%
Return-on-Assets % 37.55%
Profit Margin % 30.41%
Debt/Equity 0.00
Price/Sales 13.06
Price/Cash Flow 41.83
Price/Book 7.54
Book Value/Share 0.00
Interest Coverage 314.38
60-Month Beta 0.47
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.